Clinical trial · Interventional
Pharmaceutical Care for Patients Using Capecitabine
Impact of Pharmaceutical Care on Patients Using Capecitabine: a Multicenter Randomized Clinical Trial
NCT07063706CI-TRIAL-00092341completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a longitudinal, prospective and intervention study, which will be carried out with patients undergoing treatment with capecitabine, where the impact of pharmaceutical care will be evaluated.
Conditions
Conditions (5)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Adverse Drug Reaction (ADR) | — | UNRESOLVED | — |
| Cancer Colorectal | — | UNRESOLVED | — |
| Cancer Gi | — | UNRESOLVED | — |
| Capecitabine | — | UNRESOLVED | — |
| Pharmaceutical Services | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Pharmaceutical Care | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- NO_INTERVENTION
- label
- Control group
- description
- Participants in the control group received pharmaceutical guidance at the time of dispensing capecitabine.
- type
- ACTIVE_COMPARATOR
- label
- Pharmaceutical care
- description
- Participants in the intervention group received pharmaceutical care.
- interventionNames
- Other: Pharmaceutical Care
Primary outcomes (1)
- measure
- Instruments and questionnaire
- timeFrame
- Up to 6 months
- description
- Assessment of the clinical benefits of pharmaceutical care, measured by the variation in participants' quality of life between the beginning and end of treatment with capecitabine
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients initiating treatment with capecitabine, either: as monotherapy, or in combination with other antineoplastic therapies and/or radiotherapy. * No restrictions regarding therapeutic regimen or disease stage. * Age 18 years or older. * Patients being followed at one or both of the following institutions: Hospital do Câncer I of the National Cancer Institute (INCA), and/or Clementino Fraga Filho University Hospital (UFRJ). Exclusion Criteria: * Patients who have previously started capecitabine treatment, with more than one full cycle completed prior to enrollment. * Inability to communicate verbally or significant difficulty in understanding that prevents adherence to pharmaceutical care instructions. * Refusal or inability to sign the Informed Consent Form. * Participation in another clinical study that may interfere with outcomes related to pharmaceutical care. * Any clinical condition that, in the investigator's judgment, may compromise full participation in the study.
References
Publications (0)
Data not yet available
No reference posted for this study.